Synthetic molecules as P2X7 receptor antagonists: A medicinal chemistry update focusing the therapy of inflammatory diseases.
P2X7 antagonists
P2X7 receptor
Synthetic molecules
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
15 Oct 2023
15 Oct 2023
Historique:
received:
04
04
2023
revised:
12
07
2023
accepted:
17
08
2023
medline:
22
9
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Stimulation of the P2X7 receptor by extracellular adenosine 5'-triphosphate induces a series of responses in the organism, exceptionally protein cascades related to the proinflammatory process. This has made P2X7 a target for research on inflammatory diseases such as rheumatoid arthritis. Thus, the incessant search for new prototypes that aim to antagonize the action of P2X7 has been remarkable in recent decades, a factor that has already led to numerous clinical studies in humans. In this review, we present the key molecules developed over the years with potential inhibition of P2X7 and inflammation. In addition, an update with newly developed chemical classes with promising activity and results in clinical studies for human pathologies focusing on P2X7 inhibition.
Identifiants
pubmed: 37619787
pii: S0014-2999(23)00511-3
doi: 10.1016/j.ejphar.2023.175999
pii:
doi:
Substances chimiques
Purinergic P2X Receptor Antagonists
0
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
175999Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.